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Osteogenesis imperfecta (OI) is the most common heritable disorder of connective tissue. It is associated with fractures following
relatively minor injury, blue sclerae, dentinogenesis imperfecta, increased joint mobility, short stature, and hearing loss. Structures
in the otic capsule and inner ear share in the histologic features common to other skeletal tissues. OI is due to mutations involving
several genes, the most commonly involved are the COL1A1 or COL1A2 genes which are responsible for the synthesis of the
proalpha-1 and proalpha-2 polypeptide chains that form the type I collagen triple helix. A genotype/phenotype relationship to
hearing loss has not been established in OI. Hearing loss is commonly found in OI with prevalence rates ranging from 50 to 92%
in some studies. Hearing loss in OI may be conductive, mixed, or sensorineural and is more common by the second or third
decade. Treatment options such as hearing aids, stapes surgery, and cochlear implants are discussed.
1.Introduction
Osteogenesisimperfecta(OI)isthemostcommonoftheher-
itable disorders of bone as ﬁrst deﬁned by McKusick in 1956
[1]. Approximately 25,000 individuals with this condition
live in the US. However, the real incidence may be twice that
number because of persons with mild OI who experience
a small number of fractures and in whom no diagnosis is
made. Hearing loss is a signiﬁcant complication of OI.
The hallmark of OI is the occurrence of fractures with
relatively minor injury. Blue sclerae, dentinogenesis imper-
fecta,increased joint mobility, and short stature are common
to the 8 phenotypes that are currently recognized (Table 1).
As shown in Table 1, these vary considerably in their relative
incidence and clinical severity. It is not commonly appre-
ciated, however, that OI is a systemic disorder of connective
tissue due to the wide distribution of type I collagen in mul-
tiple organs.
Type I collagen is the most abundant protein in the
body. OI is the result of mutations involving several genes
responsible for the synthesis or intracellular processing of
typeIcollagen(COL1).Todate,7geneshavebeenimplicated
as causative in OI [2, 3]. Ninety-ﬁve percent of OI cases are
duetodominantlytransmittedmutationsinvolvingCOL1A1
or COL1A2 genes which are responsible for the synthesis of
the proalpha-1 and proalpha-2 polypeptide chains that form
the type I collagen triple helix. Approximately 3–5% of cases
involve mutations which are transmitted recessively and are
associated with severe or lethal OI. These genes modify the
intracellular processing of type I collagen: CRTAP (collagen-
relatedprotein),P3H1/LEPRE1(prolyl3-hydroxylase1),and
PPIB (Cytophyllin B protein) and several chaperone proteins
such as HSP-47 in the endoplasmic reticulum [4–6]. CRTAP
and P3H1 form a complex with cyclophilin B (CyPB) in
the endoplasmic reticulum (ER) which 3-hydroxylates the
Pro986 residue of collagen proalpha1 (1) and proalpha (2I)
chains [7]. Mutations in these genes lead to severe or lethal
skeletal disease (OI types VII and VIII) [8]. No correlation
has been established to date between mutations aﬀecting the
COL1A1 and COL1A2 genes and hearing loss in OI [9].2 Genetics Research International
Table 1: Types of osteogenesis imperfecta (adapted from [18]).
Type Inheritance∗∗ Clinical Incidence++ Mutations
IA D Mild, blue sclerae fractures with little or no deformity
hearing loss, DI 60% Type I collagen
COL1A1, COL1A2
II AD, AR Lethal, pulmonary insuﬃciency, beaded ribs, rhizomelic
hearing loss 10% Type I collagen
COL1A1, COL1A2
III AD, AR Progressive deforming intrauterine fractures, deformed
limbs, scoliosis white or blue sclerae hearing loss, DI 10% Type I collagen
COL1A1, COL1A2
IV AD Moderately severe, limb deformity, sclerae blue early and
lighten with age scoliosis 15% Type I collagen
COL1A1, COL1A2
VA D Variable phenotype like IV hyperplastic callus, dislocated
radial head calciﬁed interosseous membrane 5% Unknown
VI unknown More fractures than IV mineralization defect on biopsy,
vertebral fractures, no DI Unknown
Type I collagen
SERPINF1 (chaperone
protein)
VII AR
First nations family, Quebec
++
CRTAP, LEPRE1, PPIB
(prolyl-3 hydroxylation) congenital fractures white sclerae, severe rhizomelia
VIII AR Severe or lethal similar to OI type II (Sillence) ++ CRTAP, LEPRE1 SERPINH1
∗∗AD = autosomal dominant.
∗∗AR = autosomal recessive.
++: the incidence of OI types I–IV is reasonably established. However, for the less common types, OI types VI, VII, and VIII, the incidence is not clearly
deﬁned. However, it is estimated that the recessively inherited forms (VII and VIII) constitute approximately 3–5% of the total OI population.
As noted above, disordered type I collagen synthesis af-
fects multiple organs in addition to bone. Blue sclerae result
from altered light reﬂectance in the presence of abnormal
scleral collagen [10]. Corneal defects occur because collagen
is the dominant corneal protein. Tendon and ligament in-
volvement leads to hyperextensible joints. Dentinogenesis
imperfecta is the result of abnormal collagen in dental pulp
which leads to enamel breakage. Type I collagen in vascular
structuresleadstomitralandaorticvalveinvolvementaswell
as aortic dilatation in some cases. Finally, disordered type I
collagen in the ear involves each of the auditory structures,
bothhardandsofttissues,leadingtoearly-onsethearingloss.
There is limited information about the histopathology
of the temporal bone in OI. Berger et al. examined the
histopathologic ﬁndings in 8 temporal bones from 5 patients
with type III osteogenesis imperfecta [11]. Evidence of both
deﬁcient and abnormal ossiﬁcation was found in the bony
walls of middle ear and ossicles. Microfractures were found
in the otic capsule and in the anterior process and handle
the malleus and at the crura of the stapes. The cochlear and
vestibular end organs appeared normal. It is of interest that
the OI auditory system did not show changes compatible
with otosclerosis. Zajtchuk and Lindsay [12], reporting
on three OI cases (Type III), observed sclerotic ﬁxation
of the footplate, lack of deposition of the skein-like bone
in the endochondral layer, sparse bony septae in marrow
spaces, and a deﬁciency of the periosteal layer. The stapedial
crura were thin, deformed, and fractured in 2 cases [12].
Examination with the scanning electron microscope using
the Ca/P ratio as the criterion based on characteristic X-ray
ﬂuorescence showed that the stapes in OI had a higher Ca/P
ratio (2.6:1) as compared to the normal stapes 2:1 ratio.
The stapes in OI were poorly mineralized, with low calcium
salt and apparent increase of phosphates. This ﬁnding sug-
gested a possible change from hydroxyapatite (or apatite) to
brushite, which implied an acidiﬁcation of bone [13].
Computerized tomography (CT) of the temporal bone
in an OI type I patient demonstrated otic capsule deminer-
alization that appeared to progress as hearing diminished
[8]. Band-like areas of lucency were seen surrounding
the cochlea. Similarly, magnetic resonance imaging (MRI)
examination of the otic capsule in type I OI demonstrated
demineralized pericochlear lesions with soft tissue signal
intensity and contrast enhancement [14, 15].
2. HearingLoss inOsteogenesis Imperfecta
Hearing loss is a signiﬁcant clinical feature in many patients
with OI. In national surveys of hearing loss in OI, prevalence
rates of hearing loss of 46% [16] to 57.9% [17]h a v eb e e n
reported. In a recent study, hearing loss was found in
62% of ears with the hearing loss ranging from mild to
profound [18]. Slightly lower prevalence of hearing loss
(50%) [19, 20] or even a higher prevalence of hearing
loss (65–72%) [16, 21] has been reported. Methodological
or deﬁnitional diﬀerences may account for the varying
results across studies [22]. Some investigators have excluded
cases of conductive hearing loss believed to be secondary
to otitis media with eﬀusion (OME) in younger patients
with OI [16, 23] which would lead to underestimation of
the prevalence of hearing loss. Subject selection issues are
also a consideration. Hearing loss varies with the type of
OI and is reported to be most common in type I OI and
rarely reported in type IV OI [24]. Studies including only
t y p eIO Ip a t i e n t s[ 23] have reported a higher prevalenceGenetics Research International 3
of hearing loss in OI than studies with more inclusive
selection criteria [18]. For example, when only patients with
type I OI over 30 years of age are considered, a 95% rate of
hearinglosshasbeenreported[23].Norelationshiphasbeen
reported between the degree, nature of hearing loss, and
m u t a t e dg e n eo rm u t a t i o nt y p e[ 25]. Sykes et al. reported
that 13/16 patients with early onset of hearing loss had a
mutation in the COL1A1 gene [26]. OI may be associated
with neurological complications such as skull fractures, sei-
zuredisorders,andbrainstemcompressionsecondarytobas-
ilarinvagination[27].Someofthesecomplicationscanresult
in hearing loss. Some studies have excluded patients with
theseorothercomplicationsbelievedtobeunrelateddirectly
to OI [17], whereas others have not [18, 22].
It is frequently reported that conductive hearing loss is
found in younger patients with OI, whereas sensorineural
hearing loss is found more in older patients with OI [17,
19, 21, 23, 28]. This view is not uniform as one study has
reported that hearing loss in OI is most frequently sensor-
ineural in origin [29] in the initial presentation. However,
it should be noted that there are deﬁnitional diﬀerences
across studies in terms of how conductive and sensorineural
hearing loss are deﬁned. For example, Riedner et al. [19]
deﬁned as conductive any hearing loss in which the air-bone
gap was 5dB or greater at two or more octave frequencies
from 500 to 4000Hz. On the other hand, Shapiro et al. [29]
required a 15dB or greater air-bone gap at one or more
frequenciestoclassifyalossasconductive.Otherstudieshave
not explained how conductive versus sensorineural hearing
loss was deﬁned [28].
Several investigators have reported that hearing loss is
infrequentinOIuntilthe2ndor3rddecadeoflife,increasing
with advancing age [19, 21, 28]. However, hearing loss in
younger patients with OI is not uncommon [17, 22], and
mixed or sensorineural hearing loss may be observed at
any age [17]. When sensorineural hearing loss is found in
children, it is typically found in type I OI [17, 18]. Other
investigators have reported that hearing loss in OI is typically
sensorineural in origin [29] and begins with a characteristic
loss in the 6000–8000Hz frequency region. One recent study
reported a prevalence of sensorineural hearing loss in 12%
of ears, conductive hearing loss in 21% of ears, and mixed
hearing loss in 29% of ears [18] in patients with OI. As has
been reported in other investigations [17, 22], sensorineural
hearing loss was present in a younger age group consisting of
children(meanage =9.87)andwasfoundonlyinassociation
w i t ht y p eIO I[ 18].
The etiology of sensorineural hearing loss in OI has not
been deﬁnitively determined but may be a consequence of
atrophy of the cochlear hair cells and the stria vascularis as
well as from abnormal bone formation in the cochlea and
surrounding structures [25]. Patients with OI are at greater
risk for skull fractures which are associated with hearing
loss. The cause of conductive impairments in OI is often
associated with footplate ﬁxation [25] although fractures of
the crura do occur [30]. Atrophy of the stapes crura and
hypervascularized mucosa have also been reported [25]. An
association between conductive hearing loss due to stapes
ﬁxation and a mutation in the COL1A1 gene has been
suggested [25]. On the other hand, in a much larger study,
no relationship was found between the mutation types and
the presence, type, severity, or age of onset of hearing loss
[9].Autopsyﬁndingshaveshownhaircellloss,abnormalities
of the tectorial membrane, perilymph hemorrhage, atrophy,
and calciﬁcation of the stria vascularis in OI [31]. In
newbornswithsevereOI,evidenceofincompleteossiﬁcation
oftheoticcapsulehasbeenreportedaswellasmicrofractures
in the otic capsule, deﬁcient ossiﬁcation of the ossicles, and
microfractures in the anterior process and handle of the
malleus [11]. In older patients with OI who had been seen
surgically for stapedial ﬁxation or discontinuity, histological
examination of the recovered stapes revealed evidence of an
otospongiotic-like lesion in the footplate of the stapes [32].
CT scans in OI have revealed undermineralization of the otic
capsule [33] as well as involvement of the cochlea, semi-
circular canals, the distal internal auditory canal, and oval
window in an individual with hearing loss of mixed origin
[33]. It has been noted that in some respects the features of
hearing loss in OI such as ossicular involvement and hearing
loss progression mimic those found in otosclerosis [21].
However, OI and otosclerosis are biochemically divergent
[34]. Examination of histopathological data has shown that
OIisageneralizeddisorderoftheboneandconnectivetissue,
whereas otosclerosis is a localized disease of the temporal
bone [32]. Another diﬀerence between OI and otosclerosis is
that sensorineural hearing loss is more commonly reported
in OI than in otosclerosis and at earlier ages [17].
Hearing loss is very common in older patients with OI
and in one recent study in older patients (Mean age = 44
years) with OI, 87% of ears had some degree of hearing
loss [18]. In younger patients with OI, hearing loss was
n o ta sc o m m o nb u tw a ss t i l lp r e s e n ti n3 8 %o fe a r s[ 18].
Other studies with pediatric patients with OI have report-
ed prevalence rates ranging from 9.1% [35] to 77.3% [22].
When patients with a range of medical conditions including
otitis media with eﬀusion, skull fracture, and neonatal men-
ingitis are included in the sample studied, higher prevalence
rates are reported [22]. Some investigators [18, 22]h a v e
not made assumptions as to whether factors present in the
medical history were related or not to the complex of sym-
ptoms experienced by patients with OI. For example, the
presenceofOME,historyofheadtrauma,andbacterialmen-
ingitis were not exclusion criteria in recent investigations
as long as the patients presented with the diagnosis of OI
[18, 22].Thispracticehasbeenchallengedbysomeinvestiga-
tors [36].
Conductive hearing loss is typically reported as the
initial manifestation of hearing loss in OI [16, 17, 19].
Clinically, pediatric patients with OI may initially present
with conductive hearing loss associated with otitis media.
This clinical observation has recently been supported in two
investigations [18, 22], which have suggested the possibility
of increased susceptibility in pediatric patients with OI to
otitis media with eﬀusion. In pediatric patients with OI,
tympanometric abnormalities consistent with the presence
of middle ear eﬀusion were common in that 43% of the
sample failed tympanometry [18]. In contrast, failure rates
for tympanometry in preschool and school age children have4 Genetics Research International
been reported to be in the range of to 8.6%–13.5% [37, 38],
which suggests a higher rate of failure for tympanometry in
OI than in the general preschool and school age population.
As noted recently [18], the high incidence of otitis media
witheﬀusioninyoungerpatientswithOImaybeattributable
to the presence of craniofacial dysmorphism in OI [22]. A
high frequency of OME is also commonly observed in other
syndromes characterized by morphological abnormalities
of the temporal bone [39] or as a consequence of cranial
molding or deformation [22].
As noted recently, measurement of hearing loss and the
determination of etiology of the hearing loss presents some
challengesinOI[18].Theuseofboneconductionthresholds
in determination of hearing loss etiology is potentially con-
foundedbythepresenceofmiddleearpathology.Immobility
of the stapes footplate with consequent mechanical restric-
tion of the perilymph may alter cochlear functionsuﬃciently
to elevate bone conduction thresholds [40]. Middle ear path-
ologies contributing to increased stiﬀness in the middle ear
system impact on the ossicular inertial component of bone
conduction hearing [41]. This results in poorer bone con-
duction thresholds. For example, bone conduction thresh-
olds are known to be elevated in otosclerosis in the 2000Hz
region. Tympanometric abnormalities may not support the
presence of conductive involvement in OI as it was recently
reported that only 65% of ears with conductive hearing loss
and 48% of ears with mixed hearing loss were found to
haveabnormaltympanograms[18].Otherinvestigatorshave
reported normal tympanograms in individuals with conduc-
tive and mixed hearing loss [19]. It has been noted that it is
possible that the presence of multiple otologic pathologies
in OI may confuse the interpretation of tympanometric
ﬁndings[18].Thisisthecasebecausepathologycontributing
to high admittance may be masked by pathology resulting
in reduced admittance of the tympanic membrane/middle
ear system [42, 43]. It has been reported that the most
prevalent abnormal tympanometric types observed in young
patients with OI are consistent with the presence of middle
ear eﬀusion (AS, B, and C) [18]. In contrast, for older
patients with OI, the Type AD pattern is more commonly
found [18]. The type AD pattern is often associated with
ossiculardiscontinuityalthoughitcanalsobeconsistentwith
atrophicscarringofthetympanicmembrane.Theuseofonly
a low-frequency probe tone in these studies may explain the
poor test performance of tympanometry clinically [18, 19].
The use of a two-component higher frequency (678Hz)
tympanogram has been shown to be more accurate in
identiﬁcation of ossicular chain disruptions than when only
a2 2 6H zp r o b et o n ei su t i l i z e d[ 44].
3. Management of Hearing Loss in OI
TreatmentofhearinglossinOIcanbedividedintocategories
based on the severity of the hearing loss and the etiology.
As noted above, the loss can be conductive (involving the
ossicles, ear drum, and middle ear), sensorineural (involving
the cochlea, auditory nerve, and brain), or a combination
of both. The degree of hearing loss helps determine if any
Table 2: Results of stapedectomy in people with and without
OI. Findings depict the number of cases, percent of patients with
postoperation air-bone gap of less than 10dBHL, and percent of
patients with postoperation hearing loss.
Cases
Post-op air
bone gap
<10dB
Post-op sen-
sorineural
hearing loss
OI series
Garretsen and Cremers [49]4 0 7 8 1 . 7
Shea and Postma [50]5 1 7 5 8
Ferekidis et al.[51]9 7 5 0
Vincent et al.[52] 21 85.7 0
Non-OI series
Vincent et al. [53] 2525 94.2 0.7
intervention is necessary, and if so, what that intervention
should be.
Conductive hearing loss theoretically can be fully cor-
rected.InpeoplewithoutOI,thatisunfortunatelynotalways
possible. In people with OI, the percentages that are not
correctable are higher.
Serous Otitis Media. Fluid in the middle ear causes loss
of hearing by limiting ear drum and ossicle motion. This
occurs commonly in young children but can occur at any
age. Common causes include Eustachian tube dysfunction,
colds, ear infections, and allergies. When treatment of the
underlying cause does not resolve the ﬂuid, ventilation tubes
can be placed. The incidence of serous otitis may be higher
in OI. But the treatment outcomes are the same.
Ossicular Problems. OI can cause deformity of the ossicles
described earlier. These deformities can lead to a conductive
hearing loss from ossicular fracture and stapes footplate
ﬁxation. Surgical correction is usually possible, but results
of such surgery are signiﬁcantly worse than similar surgery
in non-OI series reports (Table 2). Stapedectomy results in
type I OI show closure of the air-bone gap to within 10db
in 75–85% compared to published results in normal patients
of 90–95%. Postoperative hearing loss is also higher in OI
patients with up to 8% losing hearing instead of the 1% seen
in the non-OI group. The reasons for the failure are easily
understood.Instapessurgery,thefootplatemaybeverythick
and highly vascular. This limits visibility and may narrow
the distance between the footplate and the inner ear balance
organs (utricle and saccule) to less than 0.5mm. Also in
all reconstructions including stapedectomy, the supporting
bonebeing usedisweakerthanandthusnotasstableasnon-
OI bone.
Treatment for sensorineural hearing loss in people with
OI is similar to people without OI. Hearing aids can help
manage sensorineural, conductive, and mixed (both sensor-
ineural and conductive) hearing loss. Since hearing aids
amplify the sound going into the ear, the amount of the loss
is more important than the cause of the loss. However, it
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loss typically have greater problems with speech recognition
and loudness processing than is the case with conductive
hearing loss. Fitting a person with OI with a hearing aid is
the same as ﬁtting someone without OI.
Cochlear Implants. –11% of patients with OI will have
hearing deterioration such that hearing aids will no longer
be useful. Cochlear implants provide an option for restoring
hearing[45–47].Theyaresurgicallyimplantedintotheinner
ear and electrically stimulate the auditory nerve directly.
Some problems have been encountered that are speciﬁc to
people with OI. The operation to implant the device can be
more diﬃcult because of the hypervascularity of the bone
and the possible narrowing of the inner dimensions of the
cochlear channel. Also, once the device is placed, the bone
does not shield the electrical stimulating current as well
becauseofthelowerbonedensity.Thiscansometimesleadto
stimulation of the facial nerve and require some of the elec-
trodes to be turned oﬀ. Despite these limitations, cochlear
implants provide great beneﬁt in deaf individuals with OI.
Bone-anchored hearing aids (BAHA). This is an alternative
treatment for conductive hearing loss and single-sided deaf-
ness. It requires one normal functioning inner ear. It also
requires that the titanium implant osseointegrates into the
bone. A hearing aid is then attached to the implant to
directly stimulate the bone. This vibration is sent to the in-
ner ear to stimulate hearing by bypassing the ossicles. This
is the same integration technology used with some dental
implants. Since many patients with OI develop bilateral sen-
sorineural hearing loss, they may not be a candidate for
the BAHA anyway. With the high percentage of people with
sensorineural hearing loss, the number of qualiﬁed BAHA
candidates will be low. To date, no data on the use of this
implant in OI is available.
Implantable hearing aids are starting to make their way
into the option list for treating hearing loss. These devices
drive the ossicular chain directly rather than ampliﬁng the
sound through air. They are attached to the ossicles surgi-
cally. Given the fragility of the ossicles in OI, they may not be
ag o o do p t i o n .H o w e v e r ,b e n e ﬁ c i a lr e s u l t so fV i b r a n tS o u n d -
Bridge implantation incombinationwithstapedectomyhave
recently been reported in a small sample of three patients
with OI [48].
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